Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate

Journal of Lipid Research

Volumn 55, Issue 8, 2014, Pages 1622-1633

  Gao, Yang ^a,b   Shen, Wei ^b   Lu, Boyu ^a   Zhang, Qingjiong ^a   Hu, Yang ^c   Chen, Ying ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Dyslipidemia; Liver; Peroxisome proliferator activated receptor ; Very low density lipoprotein; Very low density lipoprotein receptor

Indexed keywords

FENOFIBRATE; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

3T3 CELL LINE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEPG2 CELL LINE; HYPERLIPIDEMIA; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID DIET; LIPID METABOLISM; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION; TRIACYLGLYCEROL BLOOD LEVEL; 3T3-L1 CELL LINE; ANIMAL; BIOSYNTHESIS; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; UPREGULATION;

3T3-L1 CELLS; ANIMALS; FENOFIBRATE; LIVER; MICE; MICE, KNOCKOUT; PPAR ALPHA; RECEPTORS, LDL; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TRIGLYCERIDES; UP-REGULATION;

EID: 84905002314     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M041988     Document Type: Article

References (36)

1. Girach, A., D. Manner, and M. Porta. 2006. Diabetic microvascular complications: can patients at risk be identified? A review. Int. J. Clin. Pract. 60: 1471-1483. (Pubitemid 44560348)
2. Blonde, L. 2009. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve. Clin. J. Med. 76 (Suppl 5) : S4-S11.
3. Auwerx, J., K. Schoonjans, J. C. Fruchart, and B. Staels. 1996. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J. Atheroscler. Thromb. 3: 81-89.
4. Schoonjans, K., B. Staels, and J. Auwerx. 1996. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302: 93-109. (Pubitemid 26247079)
5. Fruchart, J. C., and P. Duriez. 2006. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 42: 39-64.
6. McKeage, K., and G. M. Keating. 2011. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 71: 1917-1946.
7. Guerre-Millo, M., P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J. M. Herbert, D. A. Winegar, T. M. Willson, J. C. Fruchart, et al. 2000. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275: 16638-16642. (Pubitemid 30398891)
8. Cheng, P. T., and R. Mukherjee. 2005. PPARs as targets for metabolic and cardiovascular diseases. Mini Rev. Med. Chem. 5: 741-753. (Pubitemid 41051897)
9. Améen, C., U. Edvardsson, A. Ljungberg, L. Asp, P. Akerblad, A. Tuneld, S. O. Olofsson, D. Lindén, and J. Oscarsson. 2005. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J. Biol. Chem. 280: 1224-1229.
10. Schoonjans, K., J. Peinado-Onsurbe, A. M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx. 1996. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348. (Pubitemid 26336216)
11. Auwerx, J., K. Schoonjans, J. C. Fruchart, and B. Staels. 1996. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 124 (Suppl) : S29-S37.
12. Vu-Dac, N., K. Schoonjans, V. Kosykh, J. Dallongeville, J. C. Fruchart, B. Staels, and J. Auwerx. 1995. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96: 741-750.
13. Schultze, A. E., W. E. Alborn, R. K. Newton, and R. J. Konrad. 2005. Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J. Lipid Res. 46: 1591-1595. (Pubitemid 41099325)
14. Webb, J. C., D. D. Patel, M. D. Jones, B. L. Knight, and A. K. Soutar. 1994. Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptor' mRNA. Hum. Mol. Genet. 3: 531-537.
15. Oka, K., K. Ishimura-Oka, M. J. Chu, M. Sullivan, J. Krushkal, W. H. Li, and L. Chan. 1994. Mouse very-low-density-lipoprotein receptor (VLDLR) cDNA cloning, tissue-specific expression and evolutionary relationship with the low-density-lipoprotein receptor. Eur. J. Biochem. 224: 975-982. (Pubitemid 24288861)
16. Tacken, P. J., F. D. Beer, L. C. Vark, L. M. Havekes, M. H. Hofker, and K. Willems Van Dijk. 2000. Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E. Biochem. J. 347: 357-361. (Pubitemid 30229381)
17. Takahashi, S., J. Suzuki, M. Kohno, K. Oida, T. Tamai, S. Miyabo, T. Yamamoto, and T. Nakai. 1995. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J. Biol. Chem. 270: 15747-15754.
18. Takahashi, S., J. Sakai, T. Fujino, H. Hattori, Y. Zenimaru, J. Suzuki, I. Miyamori, and T. T. Yamamoto. 2004. The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. J. Atheroscler. Thromb. 11: 200-208.
19. Takahashi, S., J. Sakai, T. Fujino, I. Miyamori, and T. T. Yamamoto. 2003. The very low density lipoprotein (VLDL) receptor-a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues. Mol. Cell. Biochem. 248: 121-127. (Pubitemid 36833649)
20. Tacken, P. J., B. Teusink, M. C. Jong, D. Harats, L. M. Havekes, K. W. van Dijk, and M. H. Hofker. 2000. LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J. Lipid Res. 41: 2055-2062. (Pubitemid 32039001)
21. Goudriaan, J. R., P. J. Tacken, V. E. Dahlmans, M. J. Gijbels, K. W. van Dijk, L. M. Havekes, and M. C. Jong. 2001. Protection from obesity in mice lacking the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 21: 1488-1493. (Pubitemid 34219813)
22. Eck, M. V., J. Oost, J. R. Goudriaan, M. Hoekstra, R. B. Hildebrand, I. S. Bos, K. W. van Dijk, and T. J. Van Berkel. 2005. Role of the macrophage very-low-density lipoprotein receptor in atherosclerotic lesion development. Atherosclerosis. 183: 230-237. (Pubitemid 41579272)
23. Chen, Y., Y. Hu, K. Lu, J. G. Flannery, and J. X. Ma. 2007. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J. Biol. Chem. 282: 34420-34428. (Pubitemid 350159486)
24. Multhaupt, H. A., M. E. Gafvels, K. Kariko, H. Jin, C. Arenas-Elliot, B. I. Goldman, J. F. Strauss 3rd, B. Angelin, M. J. Warhol, and K. R. McCrae. 1996. Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry. Am. J. Pathol. 148: 1985-1997.
25. Sanderson, L. M., M. V. Boekschoten, B. Desvergne, M. Muller, and S. Kersten. 2010. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol. Genomics. 41: 42-52.
26. Ferreira, A. V., G. G. Parreira, L. C. Porto, E. G. Mario, H. L. Delpuerto, A. S. Martins, and L. M. Botion. 2008. Fenofibrate prevents orotic acid-induced hepatic steatosis in rats. Life Sci. 82: 876-883.
27. Harano, Y., K. Yasui, T. Toyama, T. Nakajima, H. Mitsuyoshi, M. Mimani, T. Hirasawa, Y. Itoh, and T. Okanoue. 2006. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int. 26: 613-620.
28. Wyne, K. L., K. Pathak, M. C. Seabra, and H. H. Hobbs. 1996. Expression of the VLDL receptor in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16: 407-415. (Pubitemid 26084316)
29. Perman, J. C., P. Bostrom, M. Lindbom, U. Lidberg, M. StAhlman, D. Hagg, H. Lindskog, M. Scharin Tang, E. Omerovic, L. Mattsson Hulten, et al. 2011. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J. Clin. Invest. 121: 2625-2640.
30. Takazawa, T., T. Yamauchi, A. Tsuchida, M. Takata, Y. Hada, M. Iwabu, M. Okada-Iwabu, K. Ueki, and T. Kadowaki. 2009. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J. Biol. Chem. 284: 30049-30057.
31. Tao, H., S. Aakula, N. N. Abumrad, and T. Hajri. 2010. Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor. Am. J. Physiol. Endocrinol. Metab. 298: E68-E79.
32. Tao, H., and T. Hajri. 2011. Very low density lipoprotein receptor promotes adipocyte differentiation and mediates the proadipogenic effect of peroxisome proliferator-activated receptor gamma agonists. Biochem. Pharmacol. 82: 1950-1962.
33. Tan, M. H. 1978. The lipoprotein lipase system: new understandings. Can. Med. Assoc. J. 118: 675-680. (Pubitemid 8323612)
34. Wang, H., and R. H. Eckel. 2009. Lipoprotein lipase: from gene to obesity. Am. J. Physiol. Endocrinol. Metab. 297: E271-E288.
35. Yagyu, H., E. P. Lutz, Y. Kako, S. Marks, Y. Hu, S. Y. Choi, A. Bensadoun, and I. J. Goldberg. 2002. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J. Biol. Chem. 277: 10037-10043. (Pubitemid 34968113)
36. Hu, L., C. C. van der Hoogt, S. M. Espirito Santo, R. Out, K. E. Kypreos, B. J. van Vlijmen, T. J. Van Berkel, J. A. Romijn, L. M. Havekes, K. W. van Dijk, et al. 2008. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI. J. Lipid Res. 49: 1553-1561.